Treatment of autoimmune hemolytic anemia with Vinca-loaded platelets

Yeon Ahn, W. J. Harrington, John Byrnes, L. Pall, J. McCrainie

Research output: Contribution to journalArticle

Abstract

We worked with a new strategy for the treatment of autoimmune hemolytic anemia (AIHA) of the warm antibody type. Platelets were loaded with Vinca alkaloids and reacted with antiplatelet antibodies to facilitate their phagocytosis by macrophages, resulting in a measure of selective delivery of the drugs to the cells of the mononuclear phagocyte system, which destroy RBCs in AIHA. Four patients were studied. Three with AIHA refractory to splenectomy and the use of moderate doses of glucocorticoids achieved hematologic and clinical remissions. Administration of steroids was either discontinued or reduced to minimal doses after treatment. Remissions lasted three years in two patients and one year in the other. Responses were characterized by prompt prolongation of RBC survival, correction of anemia, and gradual decrease in cell-bound antibody. In one nonsplenectomized patient, the disorder did not respond. Platelet-Vinca alkaloid complex is useful in the treatment of AIHA refractory to splenectomy and use of steroids.

Original languageEnglish
Pages (from-to)2189-2194
Number of pages6
JournalJournal of the American Medical Association
Volume249
Issue number16
DOIs
StatePublished - Jun 2 1983

Fingerprint

Vinca
Autoimmune Hemolytic Anemia
Blood Platelets
Vinca Alkaloids
Splenectomy
Antibodies
Steroids
Mononuclear Phagocyte System
Therapeutics
Phagocytosis
Glucocorticoids
Anemia
Macrophages
Survival
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Treatment of autoimmune hemolytic anemia with Vinca-loaded platelets. / Ahn, Yeon; Harrington, W. J.; Byrnes, John; Pall, L.; McCrainie, J.

In: Journal of the American Medical Association, Vol. 249, No. 16, 02.06.1983, p. 2189-2194.

Research output: Contribution to journalArticle

Ahn, Yeon ; Harrington, W. J. ; Byrnes, John ; Pall, L. ; McCrainie, J. / Treatment of autoimmune hemolytic anemia with Vinca-loaded platelets. In: Journal of the American Medical Association. 1983 ; Vol. 249, No. 16. pp. 2189-2194.
@article{27923a8706c44759b2dfeb237055248f,
title = "Treatment of autoimmune hemolytic anemia with Vinca-loaded platelets",
abstract = "We worked with a new strategy for the treatment of autoimmune hemolytic anemia (AIHA) of the warm antibody type. Platelets were loaded with Vinca alkaloids and reacted with antiplatelet antibodies to facilitate their phagocytosis by macrophages, resulting in a measure of selective delivery of the drugs to the cells of the mononuclear phagocyte system, which destroy RBCs in AIHA. Four patients were studied. Three with AIHA refractory to splenectomy and the use of moderate doses of glucocorticoids achieved hematologic and clinical remissions. Administration of steroids was either discontinued or reduced to minimal doses after treatment. Remissions lasted three years in two patients and one year in the other. Responses were characterized by prompt prolongation of RBC survival, correction of anemia, and gradual decrease in cell-bound antibody. In one nonsplenectomized patient, the disorder did not respond. Platelet-Vinca alkaloid complex is useful in the treatment of AIHA refractory to splenectomy and use of steroids.",
author = "Yeon Ahn and Harrington, {W. J.} and John Byrnes and L. Pall and J. McCrainie",
year = "1983",
month = "6",
day = "2",
doi = "10.1001/jama.249.16.2189",
language = "English",
volume = "249",
pages = "2189--2194",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "16",

}

TY - JOUR

T1 - Treatment of autoimmune hemolytic anemia with Vinca-loaded platelets

AU - Ahn, Yeon

AU - Harrington, W. J.

AU - Byrnes, John

AU - Pall, L.

AU - McCrainie, J.

PY - 1983/6/2

Y1 - 1983/6/2

N2 - We worked with a new strategy for the treatment of autoimmune hemolytic anemia (AIHA) of the warm antibody type. Platelets were loaded with Vinca alkaloids and reacted with antiplatelet antibodies to facilitate their phagocytosis by macrophages, resulting in a measure of selective delivery of the drugs to the cells of the mononuclear phagocyte system, which destroy RBCs in AIHA. Four patients were studied. Three with AIHA refractory to splenectomy and the use of moderate doses of glucocorticoids achieved hematologic and clinical remissions. Administration of steroids was either discontinued or reduced to minimal doses after treatment. Remissions lasted three years in two patients and one year in the other. Responses were characterized by prompt prolongation of RBC survival, correction of anemia, and gradual decrease in cell-bound antibody. In one nonsplenectomized patient, the disorder did not respond. Platelet-Vinca alkaloid complex is useful in the treatment of AIHA refractory to splenectomy and use of steroids.

AB - We worked with a new strategy for the treatment of autoimmune hemolytic anemia (AIHA) of the warm antibody type. Platelets were loaded with Vinca alkaloids and reacted with antiplatelet antibodies to facilitate their phagocytosis by macrophages, resulting in a measure of selective delivery of the drugs to the cells of the mononuclear phagocyte system, which destroy RBCs in AIHA. Four patients were studied. Three with AIHA refractory to splenectomy and the use of moderate doses of glucocorticoids achieved hematologic and clinical remissions. Administration of steroids was either discontinued or reduced to minimal doses after treatment. Remissions lasted three years in two patients and one year in the other. Responses were characterized by prompt prolongation of RBC survival, correction of anemia, and gradual decrease in cell-bound antibody. In one nonsplenectomized patient, the disorder did not respond. Platelet-Vinca alkaloid complex is useful in the treatment of AIHA refractory to splenectomy and use of steroids.

UR - http://www.scopus.com/inward/record.url?scp=0020640140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020640140&partnerID=8YFLogxK

U2 - 10.1001/jama.249.16.2189

DO - 10.1001/jama.249.16.2189

M3 - Article

C2 - 6834615

VL - 249

SP - 2189

EP - 2194

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 16

ER -